FATE THERAPEUTICS INC's ticker is FATE and the CUSIP is 31189P102. A total of 188 filers reported holding FATE THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 4.84 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2023 | $45,953 | +76.4% | 12,287 | 0.0% | 0.00% | +100.0% |
| Q3 2023 | $26,048 | -76.9% | 12,287 | -48.0% | 0.00% | -75.0% |
| Q2 2023 | $112,545 | +60.7% | 23,644 | +92.4% | 0.00% | +33.3% |
| Q1 2023 | $70,035 | +56379.8% | 12,287 | 0.0% | 0.00% | -40.0% |
| Q4 2022 | $124 | -100.0% | 12,287 | +5.3% | 0.01% | -58.3% |
| Q3 2022 | $262,000 | -12.4% | 11,672 | -3.2% | 0.01% | -7.7% |
| Q2 2022 | $299,000 | -36.0% | 12,058 | 0.0% | 0.01% | -18.8% |
| Q1 2022 | $467,000 | -33.9% | 12,058 | 0.0% | 0.02% | -30.4% |
| Q4 2021 | $706,000 | +5.4% | 12,058 | +6.7% | 0.02% | -4.2% |
| Q3 2021 | $670,000 | -31.7% | 11,304 | 0.0% | 0.02% | -31.4% |
| Q2 2021 | $981,000 | +121.9% | 11,304 | +110.9% | 0.04% | +105.9% |
| Q1 2021 | $442,000 | – | 5,361 | – | 0.02% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 3,379,064 | $200,277,000 | 17.57% |
| Redmile Group, LLC | 12,957,222 | $767,975,000 | 13.39% |
| Copernicus Capital Management, LLC | 12,000 | $711,000 | 8.60% |
| Grosvenor Holdings, L.L.C. | 1,037,256 | $61,478,000 | 7.53% |
| DAFNA Capital Management LLC | 344,360 | $20,410,000 | 5.42% |
| Casdin Capital, LLC | 3,400,000 | $201,518,000 | 5.02% |
| Ally Bridge Group (NY) LLC | 270,000 | $16,003,000 | 4.70% |
| Darwin Global Management, Ltd. | 353,250 | $20,937,000 | 3.85% |
| Bellevue Group AG | 3,238,036 | $191,918,000 | 1.95% |
| Artal Group S.A. | 1,450,000 | $85,942,000 | 1.92% |